Effect of SGLT2 inhibitors on inflammatory markers and oxygen consumption in non-diabetic patients with STEMI undergoing primary PCI: A parallel design single blind controlled trial

IF 2.4 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart & Lung Pub Date : 2025-05-24 DOI:10.1016/j.hrtlng.2025.05.010

Huijuan Li , Xiaoming Qin , Leiguang Zhang , Shuai Liu , Jieyun Liu

{"title":"Effect of SGLT2 inhibitors on inflammatory markers and oxygen consumption in non-diabetic patients with STEMI undergoing primary PCI: A parallel design single blind controlled trial","authors":"Huijuan Li , Xiaoming Qin , Leiguang Zhang , Shuai Liu , Jieyun Liu","doi":"10.1016/j.hrtlng.2025.05.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated potential benefits, including anti-inflammatory effects, reverse left ventricular remodeling, improved myocardial fibrosis, and enhanced microcirculation. However, the potential of these drugs to improve cardiac remodeling and function in non-diabetic patients without heart failure remains unclear.</div></div><div><h3>Objective</h3><div>This study aims to evaluate the impact of the SGLT2 inhibitor (empagliflozin) on inflammatory markers and maximum oxygen consumption (VO<sub>2</sub> max) in non-diabetic patients experiencing acute ST-segment elevation myocardial infarction (STEMI) and undergoing percutaneous coronary intervention (PCI).</div></div><div><h3>Methods</h3><div>The expression levels of tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), high-sensitivity C-reactive protein (hs-CRP), and VO<sub>2</sub> max were measured and compared before and after surgery in both groups.</div></div><div><h3>Results</h3><div>Baseline levels of TNF-α, IL-10, and hs-CRP did not differ significantly between the two groups prior to treatment. One month post-treatment, both groups demonstrated reductions in TNF-α and hs-CRP levels relative to preoperative values, with the experimental group showing significantly lower levels of TNF-α and hs-CRP compared to the control group (<em>P</em> < 0.05). Additionally, the VO<sub>2</sub> max values measured one week post-surgery revealed a statistically significant difference between the two groups (<em>t</em> = 2.4, <em>P</em> = 0.03).</div></div><div><h3>Conclusion</h3><div>Empagliflozin administration in non-diabetic patients with STEMI undergoing emergency PCI may effectively reduce inflammatory markers and improve oxygen consumption capacity. These findings suggest a potential cardioprotective role for empagliflozin in this patient population.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"73 ","pages":"Pages 174-179"},"PeriodicalIF":2.4000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart & Lung","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147956325001165","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated potential benefits, including anti-inflammatory effects, reverse left ventricular remodeling, improved myocardial fibrosis, and enhanced microcirculation. However, the potential of these drugs to improve cardiac remodeling and function in non-diabetic patients without heart failure remains unclear.

Objective

This study aims to evaluate the impact of the SGLT2 inhibitor (empagliflozin) on inflammatory markers and maximum oxygen consumption (VO₂ max) in non-diabetic patients experiencing acute ST-segment elevation myocardial infarction (STEMI) and undergoing percutaneous coronary intervention (PCI).

Methods

The expression levels of tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), high-sensitivity C-reactive protein (hs-CRP), and VO₂ max were measured and compared before and after surgery in both groups.

Results

Baseline levels of TNF-α, IL-10, and hs-CRP did not differ significantly between the two groups prior to treatment. One month post-treatment, both groups demonstrated reductions in TNF-α and hs-CRP levels relative to preoperative values, with the experimental group showing significantly lower levels of TNF-α and hs-CRP compared to the control group (P < 0.05). Additionally, the VO₂ max values measured one week post-surgery revealed a statistically significant difference between the two groups (t = 2.4, P = 0.03).

Conclusion

Empagliflozin administration in non-diabetic patients with STEMI undergoing emergency PCI may effectively reduce inflammatory markers and improve oxygen consumption capacity. These findings suggest a potential cardioprotective role for empagliflozin in this patient population.

查看原文本刊更多论文

SGLT2抑制剂对行原发性PCI的非糖尿病STEMI患者炎症标志物和耗氧量的影响：一项平行设计单盲对照试验

钠-葡萄糖共转运蛋白2 （SGLT2）抑制剂已被证明具有潜在的益处，包括抗炎作用、逆转左心室重构、改善心肌纤维化和增强微循环。然而，这些药物改善无心力衰竭的非糖尿病患者心脏重塑和功能的潜力尚不清楚。目的本研究旨在评估SGLT2抑制剂（恩格列净）对急性st段抬高型心肌梗死（STEMI）并接受经皮冠状动脉介入治疗（PCI）的非糖尿病患者炎症标志物和最大耗氧量（VO2 max）的影响。方法检测两组患者手术前后肿瘤坏死因子-α (TNF-α)、白细胞介素-10 （IL-10）、高敏c反应蛋白（hs-CRP）、VO2 max的表达水平，并进行比较。结果两组患者治疗前TNF-α、IL-10和hs-CRP基线水平无显著差异。治疗1个月后，两组患者TNF-α和hs-CRP水平均较术前降低，实验组患者TNF-α和hs-CRP水平较对照组显著降低(P <；0.05)。术后1周VO2 max值两组比较差异有统计学意义（t = 2.4, P = 0.03）。结论非糖尿病STEMI患者行急诊PCI时给予恩帕列净可有效降低炎症标志物，提高耗氧能力。这些发现提示依帕列净在该患者群体中具有潜在的心脏保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Heart & Lung 医学-呼吸系统

CiteScore

4.60

自引率

3.60%

发文量

184

审稿时长

35 days

期刊介绍： Heart & Lung: The Journal of Cardiopulmonary and Acute Care, the official publication of The American Association of Heart Failure Nurses, presents original, peer-reviewed articles on techniques, advances, investigations, and observations related to the care of patients with acute and critical illness and patients with chronic cardiac or pulmonary disorders. The Journal''s acute care articles focus on the care of hospitalized patients, including those in the critical and acute care settings. Because most patients who are hospitalized in acute and critical care settings have chronic conditions, we are also interested in the chronically critically ill, the care of patients with chronic cardiopulmonary disorders, their rehabilitation, and disease prevention. The Journal''s heart failure articles focus on all aspects of the care of patients with this condition. Manuscripts that are relevant to populations across the human lifespan are welcome.